ATHX:NSD-Athersys Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 1.41

Change

0.00 (0.00)%

Market Cap

USD 0.31B

Volume

0.50M

Avg Analyst Target

N/A

Avg User Target

USD
Average Analyst Rating

N/A

Fundamental Analysis

Verdict

About

Athersys, Inc., a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions. The company's lead platform product includes MultiStem cell therapy, an allogeneic stem cell product, which is in Phase III clinical study for the treatment of patients suffering from neurological damage from an ischemic stroke, as well as in Phase II clinical study for the treatment of patients with acute myocardial infarction, and has completed Phase I clinical study for the treatment of patients suffering from leukemia or various other blood-borne cancers. It also develops MultiStem cell therapy to promote tissue repair and healing for animal patients, including those suffering from serious conditions with unmet medical needs. The company has license and collaboration agreements with Healios K.K. to develop and commercialize MultiStem cell therapy for ischemic stroke, acute respiratory distress syndrome, and ophthalmological indications, as well as for the treatment of liver, kidney, pancreas, and intestinal tissue diseases; and the University of Minnesota to develop MultiStem cell therapy platform. Athersys, Inc. was founded in 1995 and is headquartered in Cleveland, Ohio. Address: 3201 Carnegie Avenue, Cleveland, OH, United States, 44115-2634

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-09-26 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MRNA Moderna Inc

N/A

USD173.62B 50.82 41.56
BNTX BioNTech SE

N/A

USD80.87B 18.39 15.10
REGN Regeneron Pharmaceuticals Inc

N/A

USD68.33B 11.54 8.91
VRTX Vertex Pharmaceuticals Incorpo..

N/A

USD47.63B 24.21 16.63
ALXN Alexion Pharmaceuticals Inc

N/A

USD40.34B 59.23 42.56
BGNE BeiGene Ltd

N/A

USD35.82B N/A N/A
SGEN Seagen Inc

N/A

USD29.35B 50.34 39.11
GMAB Genmab A/S

N/A

USD28.40B 72.63 8.17
RPRX Royalty Pharma plc

N/A

USD22.53B 30.04 12.50
ALNY Alnylam Pharmaceuticals Inc

N/A

USD22.27B N/A N/A

ETFs Containing ATHX

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -19.43% 42% F 20% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -19.43% 42% F 20% F
Trailing 12 Months  
Capital Gain -30.88% 25% F 9% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -30.88% 25% F 9% F
Trailing 5 Years  
Capital Gain -28.06% 45% F 19% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -28.06% 45% F 18% F
Average Annual (5 Year Horizon)  
Capital Gain 10.41% 47% F 52% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 10.41% 46% F 49% F
Risk Return Profile  
Volatility (Standard Deviation) 40.81% 73% C 45% F
Risk Adjusted Return 25.52% 51% F 39% F
Market Capitalization 0.31B 47% F 41% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 10.71 15% F 13% F
Price / Cash Flow Ratio -5.07 36% F 65% D
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -197.04% 11% F 13% F
Return on Invested Capital -286.76% 3% F 2% F
Return on Assets -73.09% 5% F 2% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 8.38 27% F 16% F
Short Percent 6.17% 44% F 29% F
Beta -1.72 100% A+ 99% A+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector